At the end of July 2015, the leon-nanodrugs GmbH raised 18.5 million through a Series A financing round. The startup, founded in Munich in 2011, offers a patented technology platform that allows the formulation of small molecular and biological active ingredients as nanoparticles for oral or parenteral administration.
The financing round is considered one of the largest Series A rounds in Germany this year and is to be increased by a further three million euros at a later date in 2015.
The international financing round was led by Munich-based fund provider TVM Capital Life Science; other participants included Signet Healthcare Partners (USA), LifeCare Partners (Switzerland), CD-Venture (Germany), Albany Private Equity Holding (Australia), and an unnamed German family office.
The proceeds from the financing round will be used to expand the service business of leon-nanodrugs GMBH and to enter into co-development deals with partners in the pharmaceutical industry.
For TVM Capital Life Science, this was the first investment in a German company since 2009. The globally active group of venture capital and private equity firms manages approximately 1.3 billion US dollars.
